Biologic Therapy and Kids: Can It Kickstart Growth?
"New study explores how biologic treatments influence growth in children battling chronic inflammatory diseases, offering hope for improved development."
Chronic inflammatory connective tissue diseases (CTDs) are a group of conditions that cause long-term inflammation, and children are impacted heavily. Beyond the more obvious symptoms, one sneaky complication that flies under the radar is how these diseases can stunt growth. This happens due to the inflammation and also because of treatments like glucocorticoids (GCS), which, while helpful, can also mess with a kid's growth rate.
These growth issues are most obvious in kids with juvenile spondyloarthropathies and juvenile idiopathic arthritis (JIA). How long they've had the disease and how active the inflammation is are big factors in how much their growth is affected. But there's good news! Biologic therapies are coming in to change the game, helping to calm down disease activity and cut back on those high doses of steroids. The aim? To get these kids growing normally again.
A recent study took a closer look at just how much of an impact these biologic therapies have on growth in children with chronic inflammatory CTDs. The goal was simple: to figure out if these advanced treatments can really help kids get back on track when it comes to growing.
Growth Challenges in Children with Chronic Conditions
Growth retardation remains a significant concern for children with chronic inflammatory and autoimmune conditions. When systemic inflammation persists, it can disrupt normal growth patterns, potentially leading to long-term height deficits and associated psychosocial impacts. The precise prevalence varies across different pediatric populations and underlying diagnoses, but the issue represents an important intersection of disease management and developmental outcomes that clinicians must monitor throughout childhood.
Traditional Growth Monitoring and Intervention Methods
Standard approaches to monitoring childhood growth have historically relied on growth charts and height velocity measurements taken at regular intervals. When growth failure is identified, interventions typically address underlying disease activity alongside nutritional support and endocrine evaluation. However, these conventional methods may not always capture the nuanced relationship between disease control and growth potential, and pharmacologic interventions carry their own considerations regarding timing, dosing, and potential side effects in developing children.
Establishing Growth Standards and Developmental Benchmarks
The World Health Organization developed Child Growth Standards using data from the WHO Multicentre Growth Reference Study, establishing international benchmarks for physical growth curves and motor milestone achievement. Developmental milestones are categorized across domains including gross motor, fine motor, language, cognition, social growth, and emotional growth. Studies have established average ages at which specific milestones are reached, along with ranges of typical development, providing clinicians with systematic frameworks for assessing children's developmental trajectories and identifying potential growth concerns.
Unlocking Growth: How Biologic Therapies Work
Researchers dove into the data of 24 young patients with CTDs, all being treated with some form of biologic therapy. These included TNF-alpha blockers like etanercept, adalimumab, and golimumab, as well as an interleukin-6 receptor blocker called tocilizumab. The team checked in on these kids at three key points: when their disease first showed up, when they started on biologic treatments, and then regularly for the next one to two years.
- What They Found: At the start, the kids' height measurements (height SDS) were a bit off, averaging 0.36 ±1.07 at disease onset and dropping to -0.13 ±1.02 when they started biologic therapy. But as they continued with the biologic treatment, things started to look up.
- Growth Spurt: Over 70% of the kids saw their growth velocity pick up. On average, their height SDS improved by 0.51 ±0.58 during the two years they were on biologic therapy.
- Lower Steroid Doses: In almost half the cases, the kids were able to cut their GCS down to zero, which is a big win since these drugs can really hinder growth.
Biologic Therapies and Growth Outcomes in Juvenile Idiopathic Arthritis
A systematic review published in 2025 examined the impact of biologic treatments on growth retardation in children with juvenile idiopathic arthritis (JIA). The review analyzed twelve studies published between 2003 and 2018, encompassing 1,513 patients with a mean age of 11.4 years, following PRISMA guidelines to assess growth outcomes. Children with JIA often experience growth retardation due to various factors, and biologic therapies have revolutionized the management of aggressive forms of this condition. The systematic review aimed to provide updated insights into how these treatments influence growth parameters in pediatric patients.
Challenges and Limitations in Biologic Therapy for Pediatric Growth
Despite promising research findings, biologic therapies for enhancing pediatric growth face several challenges that warrant consideration. Treatment responses can vary significantly among individual patients, and not all children may experience the same degree of growth improvement. The long-term safety profiles of biologic agents in developing children continue to require careful monitoring, and the specialized nature of these treatments may limit accessibility for some patient populations. Additionally, factors such as disease duration and inflammatory activity levels can influence growth outcomes independently of therapeutic intervention.
Evaluating Biologic Approaches Against Conventional Treatments
When comparing biologic therapies to traditional treatment approaches for pediatric growth concerns, several factors merit consideration. Conventional management typically focuses on disease control and nutritional optimization, while biologic agents target specific inflammatory pathways implicated in growth suppression. The selection of appropriate therapy often depends on the underlying condition, disease severity, and individual patient characteristics. While biologic treatments represent an advancement in managing aggressive inflammatory conditions, they are generally considered as part of a comprehensive treatment strategy rather than standalone solutions for growth promotion.
The Bigger Picture: Why This Matters
For families dealing with chronic inflammatory conditions, this study offers some real hope. It highlights how biologic therapies can be a game-changer, not just in managing the disease but also in helping kids achieve healthy growth. By targeting inflammation and reducing the need for steroids, these treatments pave the way for a brighter, taller future.
Integrating Evidence into Clinical Practice
The evidence regarding biologic therapies and pediatric growth suggests that controlling underlying inflammatory disease remains central to supporting normal growth trajectories in affected children. Clinical decision-making must balance potential benefits against treatment risks, considering factors such as disease activity, patient age, and developmental stage. Ongoing monitoring of growth parameters alongside disease markers provides the best framework for assessing treatment effectiveness and making timely adjustments to therapeutic strategies.
Expanding Biologic Therapy Market and Pediatric Applications
The global biologic therapy market is experiencing substantial growth, with projections indicating the market could expand from approximately 308.65 billion USD in 2024 to over 450 billion USD by 2035. The United States represents a significant portion of this market, estimated at 70.22 billion USD in 2024 with projected growth to 107.77 billion USD by 2035. Industry analyses project compound annual growth rates ranging from 3.49% to 6.8% depending on market segment and geographic focus, with monoclonal antibodies representing a notable share of the biologic therapy landscape.
Addressing Systemic Barriers to Pediatric Biologic Access
Implementing biologic therapies for pediatric growth challenges requires navigating broader healthcare system considerations, including insurance coverage, specialist availability, and geographic access to treatment centers. The specialized nature of these therapies demands coordinated care among multiple healthcare providers, which can be particularly challenging in underserved regions. Ensuring equitable access to emerging biologic treatments while maintaining appropriate clinical oversight represents an ongoing challenge for healthcare systems serving pediatric populations.
Real-World Adherence and Patient Outcomes
Research examining real-world adherence to biologic therapies reveals that maintaining consistent treatment represents a significant factor in achieving optimal outcomes. Studies have documented that the activity of the inflammatory process has a significant impact on growth profiles in children with chronic inflammatory conditions. When examining growth outcomes in children receiving biologic therapy, duration of disease and timing of treatment initiation influence results. These findings underscore the importance of early intervention and sustained treatment adherence to maximize potential growth benefits.